Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Cipla Partially Exits Desano Of China; Redeploys Funds Into Biosimilars, APIs

This article was originally published in PharmAsia News

Executive Summary

The Indian drug maker has embarked on a new China strategy that includes biosimilars.

Advertisement

Related Content

Aspen's Acquisition of Sigma For APAC Expansion Comes At Time Of Generics Uncertainty In Australia
India's Cipla Unwraps Its Biosimilars Ambitions With A Presence In India And Shanghai; Earmarks $65 Million In First Push

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC081845

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel